Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Q ChenW Ma

Abstract

EpCAM is a common marker used in the detection of circulating tumor cells (CTC). Disseminated cancer cells display the characteristics of epithelial-to-mesenchymal transition events. The purpose of this study was to assess the potential of epithelial membrane protein 2 (EMP2) as a novel biomarker for CTC retrieval in breast cancer. MCF7 and MDA-MB-231 cells were stained with either anti-EpCAM or anti-EMP2 mAbs, respectively, followed by flow cytometric assay to measure their expression levels. PBMCs isolated from healthy donors were used for breast cancer cell spiking. CD45-depleted PBMCs from breast cancer patients' blood were used for CTC capturing. Immunomagnetic separation was used to enrich breast cancer cells. Cytospin centrifugation was performed to concentrate the captured cells, followed by immunofluorescence staining with anti-CD45 mAb, anti-pan cytokeratin mAb and DAPI. Fluorescent images were taken using a confocal microscope for CTC counts. MDA-MB-231 cells had 2.56 times higher EMP2 expression than MCF7 cells, and EMP2 had a significantly higher capture efficiency than EpCAM for MCF7 cells. Furthermore, anti-EMP2 was capable of capturing MCF7 cells that escaped in the flow-through of anti-EpCAM. Likewise, EMP2 had...Continue Reading

References

Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·H J GrossD Recktenwald
Feb 22, 2001·American Journal of Surgery·P D Beitsch, E Clifford
Dec 18, 2001·Seminars in Surgical Oncology·D HawesR J Cote
Aug 20, 2004·The New England Journal of Medicine·Massimo CristofanilliDaniel F Hayes
Oct 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·W Jeffrey AllardLeon W M M Terstappen
Jul 22, 2009·Cancer Letters·Panayiotis A TheodoropoulosVassilis Georgoulias
Feb 2, 2011·BMC Cancer·Johanna M GostnerGilbert Spizzo
Oct 24, 2012·Breast Cancer Research : BCR·Bas FrankenLeon W M M Terstappen
Jul 9, 2013·Journal of Laboratory Automation·Ramdane A HarouakaSi-Yang Zheng
Feb 22, 2014·Nature Reviews. Molecular Cell Biology·Samy LamouilleRik Derynck
Mar 8, 2014·Breast Cancer Research : BCR·Maryam B LustbergJeffrey J Chalmers
Dec 24, 2015·PloS One·Helen SchneckUNKNOWN Disseminated Cancer Cell Network (DCC Net) Duesseldorf
Feb 22, 2016·Molecular Oncology·Meghaan M FerreiraStefanie S Jeffrey
Mar 13, 2016·Cancer Discovery·Catherine Alix-Panabières, Klaus Pantel
Apr 10, 2016·Cancer Letters·Roberta MaltoniFrancesco Fabbri
Apr 14, 2016·Molecular and Clinical Oncology·Takashi OhnagaKazuhiro Tsukada
Jul 20, 2016·Journal of Clinical Medicine·Joema Felipe LimaJohn M S Bartlett
Oct 27, 2016·International Journal of Molecular Sciences·Michela BulfoniDaniela Cesselli
Dec 19, 2016·Frontiers in Oncology·Malgorzata Banys-PaluchowskiTanja Fehm
Jan 21, 2017·Oncology Letters·Fei LiuMei-Xiang Sang
Dec 26, 2017·Frontiers in Medicine·Gulisa Turashvili, Edi Brogi

❮ Previous
Next ❯

Citations

Oct 28, 2019·Cancers·Mohammad Khusni B Ahmat AminHisakazu Ogita
Mar 29, 2020·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Yier QiuYingjie Wu
Sep 12, 2019·Frontiers in Medicine·Michael D DonnanSusan E Quaggin
May 27, 2020·Molecular Cancer Therapeutics·Christen DillardMadhuri Wadehra

❮ Previous
Next ❯

Related Concepts